The Commission proposal for a revised Transparency Directive (“the Proposal”) is an important and necessary step towards more efficient decision-making by member states in pricing and reimbursement (P&R) of medicines. At a time when countries across the EU are seeking improved management of their healthcare systems, it is essential that the procedural aspects of P&R decision-making are brought towards similar standards of quality and efficiency.
Check out what we are reading this week.
The head of Europe's drug industry has written to EU leaders ahead of their summit this week seeking major concessions to help keep supplies of medicines flowing to crisis-hit countries like Greece and Spain. Read more.
What is the aim of HTA?
Check out what we are reading this week!
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has called for the German government to take “urgent action” regarding its pricing system, which is perceived as hindering the market entry of new, innovative medicines in the country. Read more